Close to getting his PhD, Jake Becraft was wondering what he should do with his career–and then a friend called with a PowerPoint. Becraft was at the Massachusetts Institute of Technology, completing ...
Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced the promotion of Prashant Nambiar, DVM, PhD, MBA, as Chief Scientific Officer and appointment of Ethan Cash as ...
Strand Therapeutics has added to its series A funding from last year, bringing the total to $97 million. The messenger RNA (mRNA) therapeutics company is gearing up to bring its lead drug candidate, ...
-- Financing oversubscribed; proceeds from the round will be used to expand Strand’s growing mRNA platforms into multiple immuno-oncology and disease settings, and advance lead drug into Phase 1 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Strand Therapeutics, a privately held biotech company developing next-generation, programmable mRNA therapeutics beyond vaccines, today announced that the company ...
Former Nimbus Therapeutics CEO brings proven expertise scaling platform biotech companies and executing key strategic partnerships as Strand advances its clinical pipeline BOSTON--(BUSINESS ...
BOSTON, December 15, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced that Jake Becraft, PhD, Co-founder and Chief Executive Officer, ...
Leader in mRNA therapeutics strengthens clinical development expertise with globally recognized oncology innovator Strand Therapeutics, the leader in programmable mRNA medicines, today announced the ...
During the COVID-19 pandemic, mRNA-based vaccines led the charge against the SARS-CoV-2 virus. These therapies would not have existed were it not for the painstaking mRNA research that began years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback